Yuze Wu

2.1k total citations · 3 hit papers
33 papers, 1.3k citations indexed

About

Yuze Wu is a scholar working on Oncology, Immunology and Electrical and Electronic Engineering. According to data from OpenAlex, Yuze Wu has authored 33 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Immunology and 7 papers in Electrical and Electronic Engineering. Recurrent topics in Yuze Wu's work include Cancer Immunotherapy and Biomarkers (8 papers), Immunotherapy and Immune Responses (5 papers) and Optical Network Technologies (5 papers). Yuze Wu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Immunotherapy and Immune Responses (5 papers) and Optical Network Technologies (5 papers). Yuze Wu collaborates with scholars based in China, Ireland and Australia. Yuze Wu's co-authors include Kongming Wu, Ming Yi, Mengke Niu, Qi Mei, Shuangli Zhu, Zhijun Dai, Tianye Li, Pengfei Zhou, Yuheng Yan and Haoxiang Zhang and has published in prestigious journals such as Frontiers in Immunology, Molecular Cancer and Advanced Science.

In The Last Decade

Yuze Wu

30 papers receiving 1.3k citations

Hit Papers

Myeloid-derived suppressor cells: an emerging target for ... 2022 2026 2023 2024 2022 2024 2023 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
    2022 275 citations Yuze Wu, Ming Yi et al. Molecular Cancer profile →
  2. Targeting cytokine and chemokine signaling pathways for cancer therapy
    2024 171 citations Ming Yi, Tianye Li et al. Signal Transduction and Targeted Therapy profile →
  3. Recent advances in targeted strategies for triple-negative breast cancer
    2023 160 citations Shuangli Zhu, Yuze Wu et al. Journal of Hematology & Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuze Wu China 13 585 581 396 164 156 33 1.3k
Jon Amund Kyte Norway 21 921 1.6× 947 1.6× 636 1.6× 132 0.8× 141 0.9× 49 1.6k
Danny N. Khalil United States 14 950 1.6× 637 1.1× 410 1.0× 204 1.2× 274 1.8× 40 1.6k
Stéphane Ferretti Switzerland 18 410 0.7× 373 0.6× 549 1.4× 259 1.6× 180 1.2× 32 1.4k
Si Li China 16 707 1.2× 265 0.5× 362 0.9× 124 0.8× 108 0.7× 51 1.1k
Kenneth C. Valkenburg United States 7 526 0.9× 313 0.5× 446 1.1× 233 1.4× 148 0.9× 8 1.1k
Eileen E. Parkes United Kingdom 12 541 0.9× 435 0.7× 441 1.1× 149 0.9× 157 1.0× 36 1.0k
Kristen Fousek United States 11 703 1.2× 431 0.7× 298 0.8× 113 0.7× 95 0.6× 21 1.1k
Daniel Abate‐Daga United States 20 1.1k 1.9× 555 1.0× 419 1.1× 53 0.3× 131 0.8× 43 1.4k
Benedetta Belloni Germany 18 585 1.0× 380 0.7× 587 1.5× 146 0.9× 64 0.4× 32 1.3k

Countries citing papers authored by Yuze Wu

Since Specialization
Citations

This map shows the geographic impact of Yuze Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuze Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuze Wu more than expected).

Fields of papers citing papers by Yuze Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuze Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuze Wu. The network helps show where Yuze Wu may publish in the future.

Co-authorship network of co-authors of Yuze Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Yuze Wu. A scholar is included among the top collaborators of Yuze Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuze Wu. Yuze Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wang, Xiaoqian, Simin Zhu, Yuze Wu, et al.. (2025). Influencing factors of depressive symptoms during pregnancy in Beijing, China. Frontiers in Psychiatry. 16. 1500034–1500034. 1 indexed citations
3.
Wu, Yuze, Yuheng Yan, Yarong Guo, et al.. (2025). Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis. Journal of Hematology & Oncology. 18(1). 24–24. 12 indexed citations
4.
Wu, Yuze, et al.. (2024). Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors. Cancer Communications. 44(7). 739–760. 13 indexed citations
5.
6.
Yi, Ming, Tianye Li, Mengke Niu, et al.. (2024). Blockade of CCR5+ T Cell Accumulation in the Tumor Microenvironment Optimizes Anti‐TGF‐β/PD‐L1 Bispecific Antibody. Advanced Science. 11(43). e2408598–e2408598. 15 indexed citations
7.
Yi, Ming, Tianye Li, Mengke Niu, et al.. (2024). Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduction and Targeted Therapy. 9(1). 176–176. 171 indexed citations breakdown →
8.
9.
Zhang, Xiaojun, Mengke Niu, Tianye Li, et al.. (2023). S100A8/A9 as a risk factor for breast cancer negatively regulated by DACH1. Biomarker Research. 11(1). 106–106. 7 indexed citations
10.
Niu, Mengke, Ming Yi, Yuze Wu, et al.. (2023). Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy. Journal of Hematology & Oncology. 16(1). 94–94. 61 indexed citations
11.
Zhu, Shuangli, Yuze Wu, Bin Song, et al.. (2023). Recent advances in targeted strategies for triple-negative breast cancer. Journal of Hematology & Oncology. 16(1). 100–100. 160 indexed citations breakdown →
12.
13.
Yi, Ming, Di Zhang, Bin Song, et al.. (2022). Increased expression of ECT2 predicts the poor prognosis of breast cancer patients. Experimental Hematology and Oncology. 11(1). 107–107. 12 indexed citations
14.
Yi, Ming, Mengke Niu, Yuze Wu, et al.. (2022). Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. Journal of Hematology & Oncology. 15(1). 142–142. 119 indexed citations
15.
Yi, Ming, Tianye Li, Mengke Niu, et al.. (2022). TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy. Frontiers in Immunology. 13. 1061394–1061394. 56 indexed citations
16.
Wu, Yuze, Ming Yi, Mengke Niu, Qi Mei, & Kongming Wu. (2022). Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Molecular Cancer. 21(1). 184–184. 275 indexed citations breakdown →
17.
Xu, Haixuan, et al.. (2021). Crosstalk and Power Fading in a WDM-RoF Based MFN Using Directly Modulation 3s-DBR Laser. Asia Communications and Photonics Conference 2021. T2H.3–T2H.3. 1 indexed citations
18.
Wu, Yuze, Ming Yi, Shuangli Zhu, Haiyong Wang, & Kongming Wu. (2021). Recent advances and challenges of bispecific antibodies in solid tumors. Experimental Hematology and Oncology. 10(1). 56–56. 60 indexed citations
19.
Wu, Yuze, et al.. (2019). Experimental Demonstration of a WDM-RoF Based Mobile Fronthaul With f-OFDM Signals by Using Directly Modulated 3s-DBR Laser. Journal of Lightwave Technology. 37(16). 3875–3881. 29 indexed citations
20.
Stryland, Eric W. Van, Yuze Wu, David J. Hagan, M. J. Soileau, & B. S. Wherrett. (1988). ANALYSIS OF SEMICONDUCTOR BASED OPTICAL LIMITERS.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jon Amund Kyte Breakdown of academic impact, for papers by Danny N. Khalil Breakdown of academic impact, for papers by Stéphane Ferretti Breakdown of academic impact, for papers by Si Li Breakdown of academic impact, for papers by Kenneth C. Valkenburg Breakdown of academic impact, for papers by Eileen E. Parkes Breakdown of academic impact, for papers by Kristen Fousek Breakdown of academic impact, for papers by Daniel Abate‐Daga Breakdown of academic impact, for papers by Benedetta Belloni
Rankless by CCL
2026